GLP-1及利拉鲁肽整体介绍.ppt

* * ADA American Diabetes Association EASD European Association for the Study of Diabetes AACE American Assiciation of Clinical Endocrinologists ADA/EASD Odds Ratio Liraglutide 1.8 mg vs sitagliptin 100 mg 4.50 95% CI [2.90;6.97], p 0.0001 Liraglutide 1.2 mg vs sitagliptin 2.75 95% CI [1.78;4.25], p 0.0001 AACE Odds Ratio Liraglutide 1.8 mg vs sitaplitin 100 mg 4.25 95% CI [2.55;7.08], p 0.0001 Liraglutide 1.2 mg vs sitagliptin 2.11 95% CI [1.24;3.59], p 0.0059 The estimates are from a logistic regression model with treatment as fixed effect and baseline HbA1c as covariate; 26 weeks after randomisation; LOCF FAS. * Sitagliptin weight reduction similar to placebo seen in other comparable studies * Minor hypoglycaemia: event rate events per patient-year Liraglutide 1.2 mg 0.178 Liraglutide 1.8 mg 0.370 excluding outlier 0.161 Sitaglitpin 0.106 Safety analyses – all patients Liraglutide 1.8 mg versus sitagliptin Rate ratio: 3.61 95% CI: [1.22; 10.73] P-value 0·0206 Liraglutide 1.2 mg versus sitagliptin Rate ratio: 1.61 95% CI: [0.52; 5.06] P-value 0·4108 Safety analyses – excluding outlier with 21 minor hypoglycaemic episodes Liraglutide 1.8 mg versus sitagliptin Rate ratio: 1.60 95% CI: [0.59; 4.33] P-value 0·3592 Liraglutide 1.2 mg versus sitagliptin Rate ratio: 1.64 95% CI: [0.61; 4.40] P-value 0·3289 MARK-UP: MANUSCRIPT – p 14; CTR: pages 208 and 209 * * HbA1c 7.0%, no weight gain and no hypoglycaemic events Odds ratios: Liraglutide 1.2 mg vs sitagliptin 100 mg 3.46 95% CI [2.12;5.61], p 0.0001 Liraglutide 1.8 mg vs sitagliptin 100 mg 5.46 95% CI [3.37;8.85], p 0.0001 HbA1c 7.0%, no weight gain and SBP 130 mmHg Odds ratios: Liraglutide 1.2 mg vs sitagliptin 100 mg 3.13 95% CI [1.67;5.87], p 0.0001 Liraglutide 1.8 mg vs sitagliptin 100 mg 4.80 95% CI [2.58;8.93], p 0.0001 The estimates are from a logistic regression model with treatment as fixed effect and baseline HbA1c and body weight as covariates * * nn2211-1860/current -